J9342Inj thiotepa nos 1 mg
Published CMS Medicare Part B payment-limit context for J9342, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$4.931
per 1 MG · Medicare Part B
Down 14.1%from $5.738 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$13.2587$3.9083
2024-Q4: Not published; 2025-Q1: Not published; 2025-Q2: Not published; 2025-Q3: $12.236; 2025-Q4: $10.537; 2026-Q1: $8.863; 2026-Q2: $5.738; 2026-Q3: $4.931
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Thiotepa ingredient family (FDA data as of August 20, 2026).
Thiotepa
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Thiotepa presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J9341 | Inj thiotepa (tepylute) 1 mg | $36.64 per 1 MG | $38.55 per 1 MG | Down 5.0% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.